Fig. 5From: Positive expression of NANOG, mutant p53, and CD44 is directly associated with clinicopathological features and poor prognosis of oral squamous cell carcinomaThe overall survival rate of OSCC patients according to clinicopathological tumor features, treatment modality, and immunostaining patterns of NANOG, mutant p53, and CD44. a Patients with late-stage tumors (stage III & IV) show significantly poorer survival rates (p < 0.05). b–d A positive association between the overall survival rate of OSCC patients and histopathological tumor grade, neck node metastasis, and treatment modality is observed. The well-differentiated OSCC group, negative neck node group, and surgical treatment group show significantly better long-term survival rates than the corresponding opposite groups (p < 0.01). e Enhanced expression of NANOG is associated with a poor survival rate; in particular, patients with strong or moderate expression of NANOG show significantly lower survival rates than those with weak or negative NANOG expression (p < 0.01). f Patients with mutant p53(+)-expressing tumors show a lower survival rate than those with tumors negative for mutant p53(−) (p < 0.01). g Enhanced CD44 expression tends to correlate with poor survival rates, but no statistical significance was found (p > 0.05). h OSCCs with co-expression of enhanced NANOG and mutant p53 [NANOG(++)/p53(+)] correlate with a significantly lower overall survival rate than those with weak NANOG and p53 negativity [NANOG(+/−)/p53(−)] (p = 0.014). Notably, there were no deaths in the 12 cases of NANOG(+/−)/p53(−) during the follow-up period. Different letters denote statistically significant differences between groups (p < 0.05)Back to article page